Authors


Krasimir Vasilev

Latest:

Controlled Release from Porous Platforms

The authors present a method for controlling the release of therapeutics by applying a plasma polymer layer to the surface of porous materials.


Gordon Haines

Latest:

Why Training Matters

Investing in worker training is crucial to the success of a company. This article reviews the benefits of a robust training program in pharmaceutical bulk manufacturing.


Marcus Spreen

Latest:

Why Training Matters

Investing in worker training is crucial to the success of a company. This article reviews the benefits of a robust training program in pharmaceutical bulk manufacturing.


T. De Beer

Latest:

Understanding Fluidized-Bed Granulation

This study demonstrates the beneficial use of a spatial-filter velocimetry particle-size analyzer during granulation.



Bob Serfas

Latest:

Best Practices for Color Coding

Pharmaceutical manufacturing facilities can help prevent contamination and cross contamination by using color coding.


Ambuj Jain

Latest:

Emerging Markets—An Opportunity for Pharma to Drive Sustainable Growth

Cambridge Consultants engaged in a workshop-style dialogue with a cross section of senior personnel from both Indian and multinational pharma companies to debate whether emerging markets are an opportunity to drive sustainable growth. Conclusions from the workshop are presented in this article.



Bob McDowall

Latest:

Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?

Analysts should understand how a monograph, together with the associated general notices and general chapters, relate to their responsibilities under good manufacturing practices.


Patricia Santos-Serrao

Latest:

Reducing the Documentation Burden in Process Validation

The author discusses the collection and evaluation of data part of FDA’s definition of process validation.



Courtney M. Callis

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.


Bruce D. Naumann

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.


Gretchen Allison

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.


Wendy Luo

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.


Allan Ader

Latest:

Cleaning Limits—Why the 10-ppm Criterion should be Abandoned

The 10-ppm criterion for the acceptable concentration of potential API in cleaning validation to minimize cross contamination into next product has been employed for many years. This article describes why the 10-ppm criterion, which was established based on analytical limitations and estimates of acceptability, is no longer necessary and why a risk-based approach should be universally adopted.


Andreas Flueckiger

Latest:

Cleaning Limits—Why the 10-ppm and 0.001-Dose Criteria Should be Abandoned, Part II

Conventional limit-setting techniques are not health-based and can make risk assessment more difficult.


Michel Crevoisier

Latest:

Process Validation: Do We Need Brainwashing?

Six years after the guidance, it’s time to change our quality assurance vocabulary.


David G. Dolan

Latest:

Comparison of Permitted Daily Exposure with 0.001 Minimal Daily Dose for Cleaning Validation

In this study, the authors investigated the relationship between the 0.001 MinDD and the PDE values for 140 drug substances as an attempt to identify high-risk groups of products for patient safety. This comparison can serve as a method for prioritization of APIs for development of PDEs.


Ester Lovsin Barle

Latest:

Comparison of Permitted Daily Exposure with 0.001 Minimal Daily Dose for Cleaning Validation

In this study, the authors investigated the relationship between the 0.001 MinDD and the PDE values for 140 drug substances as an attempt to identify high-risk groups of products for patient safety. This comparison can serve as a method for prioritization of APIs for development of PDEs.


Bryan K. Shipp

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.


Christopher Seaman

Latest:

EMA Guideline on Setting Health-Based Exposure Limits

The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.




Mattias Haag

Latest:

Calculating And Understanding Particulate Contamination Risk

The author presents a method to calculate the relationship between supply air volume flow and airborne particle concentrations.


Michalakis Savva

Latest:

Error Assessment of Drug Concentration in Multicomponent Pharmaceutical Mixtures

A novel method, based on differential calculus, was used to calculate the maximum potential error associated with the drug concentration in pharmaceutical mixtures composed of an infinite number of ingredients measured on an infinite number of balances with different sensitivities. The method was further applied to calculate the ingredients’ least allowable quantities. This approach ensures that the pharmaceutical formulation is prepared within a given maximum permissible error in drug dose.